Borz is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma.
FDA approves subcutaneous and intravenous administration of Volz for the treatment of multiple myeloma and mantle cell lymphoma
Leave a comment
